Lv626
1820 积分 2024-09-13 加入
Tafolecimab, a Third Monoclonal Antibody for PCSK9 as the Novel Lipid-Lowering Drug Around the World: A Narrative Review
16天前
已完结
Does siRNA-based therapy require pegylated interferon-alfa-2a to cure HBV infection?
1个月前
已完结
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989
2个月前
已完结
Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA Therapeutic
4个月前
已完结
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
4个月前
已完结
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection
4个月前
已完结
Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis
4个月前
已完结
PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double- blind, placebo-controlled, multicenter SHAWN study
5个月前
已完结
Therapy for Hyperlipidemia
7个月前
已完结
皖公网安备34019202002308
